Autologous T-cell product expanded ex vivo; provides tumor-reactive lymphocytes that mediate TCR-dependent cytotoxicity as adoptive cell therapy.
Autologous tumor-draining lymph node–derived T cells expanded ex vivo and reinfused to provide tumor-reactive lymphocytes that recognize tumor antigens via native TCRs and kill target cells through perforin/granzyme cytotoxicity and cytokine-mediated immune activation.
YES
DIRECT
Adoptively transferred T cells recognize the tumor peptide–HLA-C complex via native TCRs and kill targets through perforin/granzyme-mediated apoptosis (with possible Fas–FasL/cytokine contributions).
Autologous T-cell product expanded ex vivo; provides tumor-reactive lymphocytes that mediate TCR-dependent cytotoxicity as adoptive cell therapy.
Autologous tumor-draining lymph node–derived T cells expanded ex vivo and reinfused to provide tumor-reactive lymphocytes that recognize tumor antigens via native TCRs and kill target cells through perforin/granzyme cytotoxicity and cytokine-mediated immune activation.
YES
DIRECT
Native TCRs on the infused tumor-reactive T cells recognize the tumor antigen peptide–HLA-DR complex and directly kill the presenting cell via perforin/granzyme and Fas–FasL apoptotic pathways.
Autologous T-cell product expanded ex vivo; provides tumor-reactive lymphocytes that mediate TCR-dependent cytotoxicity as adoptive cell therapy.
Autologous tumor-draining lymph node–derived T cells expanded ex vivo and reinfused to provide tumor-reactive lymphocytes that recognize tumor antigens via native TCRs and kill target cells through perforin/granzyme cytotoxicity and cytokine-mediated immune activation.
YES
DIRECT
Native TCRs on the infused lymphocytes recognize the tumor antigen peptide–HLA-DP complex and directly kill target cells via perforin/granzyme-mediated cytolysis (and related T-cell cytotoxic pathways).
Autologous gene-modified T cells expressing a chimeric antigen receptor targeting cadherin-17 (CDH17), infused intravenously to mediate targeted cytotoxicity against CDH17-positive tumors after lymphodepletion.
Autologous T cells are engineered to express a chimeric antigen receptor targeting cadherin-17 (CDH17). Upon binding CDH17 on tumor cells, CAR signaling activates T-cell effector functions, leading to proliferation, cytokine release, and targeted cytotoxic killing of CDH17-positive tumors following lymphodepleting conditioning.
YES
DIRECT
Anti-CDH17 CAR-T cells bind CDH17 on target cells, become activated, and kill them via T cell effector mechanisms (perforin/granzyme-mediated apoptosis and death receptor pathways).
Autologous T-cell product expanded ex vivo; provides tumor-reactive lymphocytes that mediate TCR-dependent cytotoxicity as adoptive cell therapy.
Autologous tumor-draining lymph node–derived T cells expanded ex vivo and reinfused to provide tumor-reactive lymphocytes that recognize tumor antigens via native TCRs and kill target cells through perforin/granzyme cytotoxicity and cytokine-mediated immune activation.
YES
DIRECT
Native TCRs on reinfused tumor-reactive T cells recognize the tumor antigen peptide–HLA-DQ complex and kill the presenting cell via perforin/granzyme (and Fas–FasL) cytotoxicity.